Publisher
Deutscher Arzte-Verlag GmbH
Reference10 articles.
1. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF), Deutschen Krebsgesellschaft e.V. (DKG) und der Stiftung Deutsche Krebshilfe (DKH). Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (DGP): S3-Leitlinie Lungenkarzinom 2022. https://www.leitlinienprogramm-onkologie.de/leitlinien/lungenkarzinom. Entnommen 14. März 2024.
2. Zeng H, Zheng D, Witlox WJA, Levy A, Traverso A, Kong FS, Houben R, De Ruysscher DKM, Hendriks LEL: Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol 10 June 2022; 12: 889161; DOI: 10.3389/fonc.2022.889161. PMID: 35756675; PMCID: PMC9226404.
3. Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 12 August 1999; 341 (7): 476–84; DOI: 10.1056/NEJM199908123410703. PMID: 10441603.
4. Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, Snee M, Hatton M, Postmus PE, Collette L, Senan S: Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 1 January 2009; 27 (1): 78–84; DOI: 10.1200/JCO.2008.17.0746. Epub 1 December 2008. Erratum in: J Clin Oncol 20 February 2009; 27 (6): 1002. PMID: 19047288; PMCID: PMC2645093.
5. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N: Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol May 2017; 18 (5): 663–71; DOI: 10.1016/S1470–2045(17)30230–9. Epub 23 March 2017. PMID: 28343976.